Grant ID | DP250149 |
Awarded On | November 20, 2024 |
Title | Functional assay of immunoproteasome for patient stratification to checkpoint inhibitor therapy using single-molecule protein sequencing |
Program | Product Development Research |
Award Mechanism | Seed Awards for Product Development Research |
Institution/Organization | Erisyon, INC |
Principal Investigator/Program Director | Jagannath Swaminathan |
Cancer Sites | Lung and Bronchus |
Contracted Amount |
$2,157,173* *Pending contract negotiation |
Lay Summary |
Our project aims to improve advanced-stage non-small cell lung cancer (NSCLC) treatment by identifying patients resistant to immune checkpoint inhibitors (ICIs). ICIs help the immune system attack cancer cells, but many advanced NSCLC patients do not respond well, leading to poor outcomes and a five-year survival rate of only 20%. This resistance is often due to a lack of tumor " antigenicity," where tumor cells do not display enough signals to attract an immune response. Dr. Yifat Merbl's research found that high levels of the protein PSME4 inhibit these signals, leading to resistance. Erisyon will use its single-molecule protein sequencing technology to measure the ratio of PSME4... |